drugset / Trial / NCT02281409
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Phase 1/2
Completed
17 enrolled
Memorial Sloan Kettering Cancer Center
Kyowa Hakko Kirin Pharma, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, KW-0761, an investigational drug, has on the patient and their cancer.
Timeline
- Start
- 2014-10
- Primary completion
- 2020-02
- Completion
- 2020-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mogamulizumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Mogamulizumab | Monoclonal antibody | 10 mg/kg | Intravenous |